RecruitingNCT07159750

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Enrollment

700 participants

Start Date

Jan 2, 2024

Study Type

OBSERVATIONAL

Conditions

Migraine Episodic Migraine Chronic Migraine, Headache

Summary

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CGRP antibody or gepant for people with chronic migraine, headache, episodic migraine, and other related conditions. The study is currently recruiting participants at 26 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCGRP antibody or gepant

Patients will start anti-CGRP or its receptor antibody or gepants

Locations(26)

University of Miami, Miller School of Medicine

Miami, Florida, United States

FLENI

Buenos Aires, Argentina

Pontificia Universidad Católica de Chile

Santiago, Chile

Neuromedica

Medellín, Colombia

Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno

Rovinj, Croatia

Charité Universitätsmedizin Berlin

Berlin, Germany

LMU University Hospital

München, Germany

University of L'Aquila

L’Aquila, Italy

University of Modena and Reggio Emilia

Modena, Italy

National Neurological Institute C. Mondino Foundation

Pavia, Italy

IRCCS San Raffaele

Roma, Italy

Universiti Putra Malaysia

Serdang, Selangor, Malaysia

Neuroclinic Norway

Lillestrøm, Norway

Wrocław Medical University

Wroclaw, Poland

Hospital Santa Maria Lisbon

Lisbon, Portugal

Germans Trias i Pujol Hospital

Badalona, Barcelona, Spain

Vall d'Hebron University Hospital

Barcelona, Barcelona, Spain

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Fundació Sanitària Mollet

Mollet del Vallès, Barcelona, Spain

Hospital de Viladecans

Viladecans, Barcelona, Spain

Hospital General Universitario de Albacete

Albacete, Spain

Fundación Jiménez Díaz

Madrid, Spain

Hospital Universitario Gregorio Marañón

Madrid, Spain

La Paz University Hospital

Madrid, Spain

Hospital Clínico Universitario Lozano Blesa

Zaragoza, Spain

Mersin University

Mersin, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07159750

Related Trials

Mind Body Balance for Pediatric Migraine

NCT047156852 locations

Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine.

NCT075005582 locations

BE WELL With Migraine: Brain Education and WELLness With Migraine

NCT059875923 locations

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT0589732065 locations

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT0516417270 locations